Clinical Report: Tylenol in Pregnancy: New Review

Overview

A systematic review found no association between prenatal paracetamol exposure and neurodevelopmental disorders such as autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), or intellectual disability. These findings support the continued recommendation of paracetamol as a safe analgesic during pregnancy.

Background

Paracetamol is the most commonly recommended analgesic and antipyretic during pregnancy, yet concerns about its potential neurodevelopmental effects have persisted. Conflicting observational evidence has led to increased scrutiny of its safety profile. Understanding the implications of prenatal paracetamol exposure is crucial for guiding clinical recommendations and ensuring maternal and fetal health.

Data Highlights

No significant associations were found in pooled analyses of sibling-comparison designs regarding prenatal paracetamol exposure and neurodevelopmental outcomes.

Key Findings

• Pooled analyses showed no association between prenatal paracetamol exposure and ASD, ADHD, or intellectual disability.
• Findings remained consistent in studies with low risk of bias and those with over 5 years of follow-up.
• Quality assessment of included studies indicated 11 at low risk, 23 at moderate risk, and 9 at high risk of bias.
• Definitions of paracetamol exposure varied, with many studies relying on maternal self-report, increasing the risk of misclassification.
• Meta-analyses indicated pooled estimates were close to null across various analytical approaches.

Clinical Implications

Clinicians can continue to recommend paracetamol for pain and fever management in pregnant patients, as current evidence does not indicate significant risks for neurodevelopmental disorders. Ongoing monitoring and education about the appropriate use of paracetamol during pregnancy remain essential.

Conclusion

The current systematic review reinforces the safety of paracetamol use during pregnancy, alleviating concerns regarding its association with neurodevelopmental disorders. Continued adherence to established guidelines is advised.

References

1. D'Antonio F, Flacco ME, et al., The Lancet: Obstetrics, Gynaecology, & Women’s Health, 2025 -- Tylenol in Pregnancy: New Review
2. Associated Press Health — Tylenol use drops among some pregnant women after Trump's unproven autism claim
3. Associated Press Health — New research adds to evidence that Tylenol doesn't raise autism risk
4. The New Gastroenterologist — Updated Recommendations for Managing Pregnancy in Women with Inflammatory Bowel Disease to Alleviate Concerns
5. ada news — ADA advocates for peer-reviewed science after Trump administration links Tylenol to autism
6. Tylenol use drops among some pregnant women after Trump's unproven autism claim
7. New research adds to evidence that Tylenol doesn't raise autism risk
8. Updated Recommendations for Managing Pregnancy in Women with Inflammatory Bowel Disease to Alleviate Concerns
9. ADA advocates for peer-reviewed science after Trump administration links Tylenol to autism
10. Acetaminophen Use in Pregnancy and Neurodevelopmental Outcomes | ACOG
11. Acetaminophen Use During Pregnancy and Children’s Risk of Autism, ADHD, and Intellectual Disability | JAMA
12. Prenatal paracetamol exposure and child neurodevelopment: a systematic review and meta-analysis - SORA